People are discussing JXL-069 (PP405) for hair loss, with some experimenting with a 0.05% topical gel. Concerns about safety and efficacy persist due to limited testing and lack of official approval.
The user has not seen results from various hair loss treatments including finasteride, dutasteride, minoxidil, and others over several years and is considering adding RU58841 and starting hormone replacement therapy. They are also experiencing anxiety and contemplating moving to a more accepting environment for their nonbinary identity.
The user switched from finasteride and topical minoxidil to dutasteride and oral minoxidil, questioning the effectiveness and safety of continuing RU58841. They experienced hair loss improvement initially but are now considering stopping RU58841 due to cost and safety concerns.
RU58841 is considered effective by some users, but finasteride and minoxidil are commonly used with varying dosages to manage side effects. Users report different experiences with treatments like pyrilutamide, fluridil, and RU58841, with some seeing results and others not.
The conversation is about using alfatradiol (17α-estradiol) as a hair loss treatment. The user is considering adding it to their regimen due to its safety and availability.
Treatments for hair loss, with the user considering Pyrilutamide and RU58841 as options. It is noted that although Pyrilutamide has been studied more and is allegedly more effective, there are doubts about its authenticity in the market. KX-826 is suggested as an alternative as it has a stronger effect than RU58841 and there is scientific research on it.
A user is considering using RU58841 for female pattern baldness and is also planning to use Minoxidil. They are hesitant to ask their doctor for spironolactone due to its cosmetic nature and are experiencing significant hair loss possibly due to stress and hormonal issues.
Pyluritamide and RU58841 are compared for effectiveness in addition to dutasteride for hair loss treatment. Reddit users report great results with RU58841, but data suggests pyluritamide may have better affinity.
PP405 (Everychem 3HP) may help with hair regrowth, with mixed user experiences. Users often combine it with minoxidil and finasteride, but there are concerns about its efficacy and side effects.
GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.
RU58841 is discussed as a treatment that stops scalp itching when used with finasteride or dutasteride. The user is considering trying RU58841 due to persistent itching despite using the "big 3" treatments.
PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.
The user is using Dutasteride, Nizoral, and RU58841 for hair loss and is considering mixing RU58841 with Stemoxydine for better scalp coverage but is concerned about the potential degradation of RU58841 when mixed with a water-based solution. They are seeking advice on the feasibility of this mixture.
The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.
PP405 shows promise for hair follicle reactivation with minimal side effects. Users recommend continuing Minoxidil and Finasteride until more results are confirmed.
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. User asks if RU58841 powder mixed in stemoxydine needs refrigeration and if it maintains quality at room temperature like pre-mixed solutions.
Clascoterone 5% solution is discussed as a potential new treatment for hair loss, offering an alternative for those who can't use finasteride or need additional options beyond minoxidil. Concerns about cost, effectiveness, and safety compared to existing treatments like RU58841 and finasteride are highlighted.
GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.
A 30-year-old man experienced significant hair loss after starting testosterone replacement therapy (TRT), which did not improve with daily finasteride and minoxidil. He is considering restarting TRT and is seeking advice on using pyrilutamide or RU58841 to prevent further hair loss.
RU58841 and Minoxidil can cause heart-related side effects like chest pain and heart racing. Pyrilutamide is suggested as a safer alternative, though it's new and costly.
Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.
People are discussing hair loss treatments, including pyrilutamide, minoxidil, dutasteride, alfatradiol, and bimatoprost. Users share their experiences and side effects, noting that pyrilutamide is considered more effective and safer than RU58841.
PP405 shows promise in hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil, with significant results in just four weeks. The treatment is still in early stages, with further trials needed to determine its long-term effectiveness and optimal dosage.
Combining topical finasteride with RU58841 for hair loss treatment. Users discuss the effectiveness and potential side effects of oral and topical finasteride.
RU58841 and pyrilutamide are being discussed as potential hair loss treatments, with some users reporting side effects. There is interest in these treatments as alternatives to 5ar inhibitors and oral minoxidil due to concerns about safety and side effects.
The conversation discusses Melatonin's potential benefits for AGA and a product called "Asatex" by ASATONA AG. The company was uncooperative when contacted for purchase inquiries.